Axsome Therapeutics
AXSM
409 hedge funds and large institutions have $6.41B invested in Axsome Therapeutics in 2026 Q1 according to their latest regulatory filings, with 71 funds opening new positions, 145 increasing their positions, 142 reducing their positions, and 52 closing their positions.
37% more first-time investments, than exits
New positions opened: 71 | Existing positions closed: 52
28% more call options, than puts
Call options by funds: $140M | Put options by funds: $110M
3% more funds holding
Funds holding: 398 → 409 (+11)
2% more repeat investments, than reductions
Existing positions increased: 145 | Existing positions reduced: 142
0.55% less ownership
Funds ownership: 74.66% → 74.11% (-0.55%)
7% less capital invested
Capital invested by funds: $6.86B → $6.41B (-$457M)
31% less funds holding in top 10
Funds holding in top 10: 13 → 9 (-4)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
First Trust Advisors
Wheaton,
Illinois
|
+$92.2M |
| 2 |
Point72 Asset Management
Stamford,
Connecticut
|
+$70.3M |
| 3 |
Assenagon Asset Management
Senningerberg,
Luxembourg
|
+$68.7M |
| 4 |
Fidelity Investments
Boston,
Massachusetts
|
+$66.6M |
| 5 |
Adage Capital Partners
Boston,
Massachusetts
|
+$63.9M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RI
RTW Investments
New York
|
-$162M |
| 2 |
NNPTE
Nationale-Nederlanden Powszechne Towarzystwo Emerytalne
Warszawa,
Poland
|
-$50.9M |
| 3 |
VPC
Vestal Point Capital
New York
|
-$38.4M |
| 4 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$33.3M |
| 5 |
Marshall Wace
London,
United Kingdom
|
-$31M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
BFPW
451
BOK Financial Private Wealth
Denver,
Colorado
| – | -$91.3K | -500 | Closed |
|
|
CIAM
452
Caitong International Asset Management
Hong Kong
| – | -$75.8K | -415 | Closed |
|
453
Daiwa Securities Group
Tokyo,
Japan
| – | -$26K | -145 | Closed |
|
|
DB
454
Danske Bank
Copenhagen K,
Denmark
| – | -$18.3K | -100 | Closed |
|
|
NA
455
NewEdge Advisors
New Orleans,
Louisiana
| – | -$9.13K | -50 | Closed |
|
|
OCM
456
Orion Capital Management
Coronado,
California
| – | -$9.13K | -50 | Closed |
|
|
CCA
457
Cygnus Capital Advisors
Atlanta,
Georgia
| – | -$6 | -33 | Closed |
|
|
MAM
458
Meeder Asset Management
Dublin,
Ohio
| – | -$5.48K | -30 | Closed |
|
|
TM
459
Torren Management
San Diego,
California
| – | -$5.11K | -28 | Closed |
|
|
CWP
460
Concord Wealth Partners
Abingdon,
Virginia
| – | -$183 | -1 | Closed |
|
|
DF
461
Dunhill Financial
London,
United Kingdom
| – | -$136 | -1 | Closed |
|
AXSM Hedge Fund Activity: Q1 2026 in Review
409 of the 8,126 institutional investors tracked by Wall St. Rank reported a position in Axsome Therapeutics (AXSM) for Q1 2026, worth a combined $6.41B — down 6.7% from $6.86B a quarter earlier.
Buyers outnumbered sellers: 71 funds opened new AXSM positions and 52 closed out — a net gain of 19 holders — while 145 added to existing stakes and 142 trimmed.
The largest buyer was First Trust Advisors, adding an estimated $92.2M. The largest seller was RTW Investments, exiting entirely with an estimated $162M sold.
- 409 institutional investors held Axsome Therapeutics (AXSM) as of Q1 2026, up from 398 in Q4 2025.
- Funds reported $6.41B of Axsome Therapeutics stock for Q1 2026, down 6.7% quarter-over-quarter.
- 71 funds opened new Axsome Therapeutics positions in Q1 2026 and 52 closed out, a net change of +19 holders.
- The largest Axsome Therapeutics buyer in Q1 2026 was First Trust Advisors, an estimated $92.2M added.
- The largest Axsome Therapeutics seller in Q1 2026 was RTW Investments, an estimated $162M sold.
Based on aggregated 13F filings for Q1 2026.